Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies

被引：0

作者：

Aejaz Nasir

Timothy R. Holzer

Mia Chen

Michael Z. Man

Andrew E. Schade

机构：

[1] Eli Lilly and Company,Diagnostic and Experimental Pathology

[2] Eli Lilly and Company,Oncology Statistics

[3] Eli Lilly and Company,undefined

[4] Lilly Corporate Center,undefined

来源：

Cancer Cell International | / 17卷

关键词：

Breast cancer; HER2; Angiogenesis; VEGFR2; Ramucirumab; Antiangiogenic therapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
Allan Lipton
Laurie Goodman
Kim Leitzel
Jennifer Cook
Jeff Sperinde
Mojgan Haddad
Wolfgang J. Köstler
Weidong Huang
Jodi M. Weidler
Suhail Ali
Alicia Newton
Eva-Marie Fuchs
Agnes Paquet
Christian F. Singer
Reinhard Horvat
Xueguang Jin
Joyee Banerjee
Ali Mukherjee
Yuping Tan
Yining Shi
Ahmed Chenna
Jeff Larson
Yolanda Lie
Thomas Sherwood
Christos J. Petropoulos
Stephen Williams
John Winslow
Gordon Parry
Michael Bates
Breast Cancer Research and Treatment, 2013, 141 : 43 - 53
[22] HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
Lipton, Allan
Goodman, Laurie
Leitzel, Kim
Cook, Jennifer
Sperinde, Jeff
Haddad, Mojgan
Koestler, Wolfgang J.
Huang, Weidong
Weidler, Jodi M.
Ali, Suhail
Newton, Alicia
Fuchs, Eva-Marie
Paquet, Agnes
Singer, Christian F.
Horvat, Reinhard
Jin, Xueguang
Banerjee, Joyee
Mukherjee, Ali
Tan, Yuping
Shi, Yining
Chenna, Ahmed
Larson, Jeff
Lie, Yolanda
Sherwood, Thomas
Petropoulos, Christos J.
Williams, Stephen
Winslow, John
Parry, Gordon
Bates, Michael
BREAST CANCER RESEARCH AND TREATMENT, 2013, 141 (01) : 43 - 53
[23] Novel artemisinin derivative FO8643 with anti-angiogenic activity inhibits growth and migration of cancer cells via VEGFR2 signaling
Lu, Xiaohua
Blatt, Sebastian
Dawood, Mona
Klauck, Sabine M.
Fleischer, Edmond
Kammerer, Peer W.
Efferth, Thomas
EUROPEAN JOURNAL OF PHARMACOLOGY, 2022, 930
[24] Rhodanine-Piperazine Hybrids as Potential VEGFR, EGFR, and HER2 Targeting Anti-Breast Cancer Agents
Szczepanski, Jacek
Khylyuk, Dmytro
Korga-Plewko, Agnieszka
Michalczuk, Mariola
Mandziuk, Slawomir
Iwan, Magdalena
Trotsko, Nazar
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)
[25] p95HER2 expression in HER2-positive breast cancer with primary resistance
Goh, Chih Wan
Yang, Benlong
Chi, Yayun
Wu, Jiong
PRECISION MEDICAL SCIENCES, 2024, 13 (02): : 99 - 106
[26] HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
Cai, Mengyuan
Li, Ming
Lv, Hong
Zhou, Shuling
Xu, Xiaoli
Shui, Ruohong
Yang, Wentao
BMC CANCER, 2023, 23 (01)
[27] Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies
Pinto, Ana Catarina
Ades, Felipe
de Azambuja, Evandro
Piccart-Gebhart, Martine
BREAST, 2013, 22 : S152 - S155
[28] Low expression of HER2 protein in breast cancer is biologically significant
Tovey, S. M.
Reeves, J. R.
Stanton, P.
Ozanne, B. W.
Bartlett, J. M. S.
Cooke, T. G.
JOURNAL OF PATHOLOGY, 2006, 210 (03) : 358 - 362
[29] Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies
Faes, Seraina
Uldry, Emilie
Planche, Anne
Santoro, Tania
Pythoud, Catherine
Demartines, Nicolas
Dormond, Olivier
ONCOTARGET, 2016, 7 (52) : 86026 - 86038
[30] A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer
Nixon, N. A.
Hannouf, M. B.
Verma, S.
EUROPEAN JOURNAL OF CANCER, 2018, 89 : 72 - 81

← 1 2 3 4 5 →